As of Wednesday close, Brainstorm Cell Therapeutics Inc.’s (NASDAQ:BCLI) stock was down -$0.19, moving down -9.74 percent to $1.76. The average number of shares traded per day over the past five days has been 288,540 shares. 3 times new highs have been achieved over the past 5 days, with a $0.0800 gain in that time frame. In the last twenty days, the average volume was 336,330, while in the previous 50 days, it was 282,200.
Since last month, BCLI stock retreated -50.35%. Shares of the company fell to $1.0854 on 11/10/22, the lowest level in the past month. A 52-week high of $4.70 was reached on 08/15/22 after having rallying from a 52-week low of $1.09. Since the beginning of this year, BCLI’s stock price has dropped by -56.00% or -$2.2400, and marked a new high 2 times. However, the stock has declined by -62.55% since its 52-week high.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
In the three months ended June 29, Brainstorm Cell Therapeutics Inc.’s quick ratio stood at 0.80, while its current ratio was 0.80, showing that the company is not able to pay off its debt.
While analysts expected Brainstorm Cell Therapeutics Inc. to report -$0.15 quarterly earnings, the actual figure was -$0.19 per share, beating the consensus estimate by -26.70%. The liabilities of Brainstorm Cell Therapeutics Inc. were 11.87 million at the end of its most recent quarter ended June 29, and its total debt was $4.74 million. The value of shareholders’ equity is $36.54 million.
This quick technical analysis looks at Brainstorm Cell Therapeutics Inc.’s (BCLI) price momentum. With a historical volatility rate of 171.72%, the RSI 9-day stood at 35.01% on 23 November.
With respect to its five-day moving average, the current Brainstorm Cell Therapeutics Inc. price is up by +4.76% percent or $0.0800. At present, BCLI shares trade -50.28% below its 20-day simple moving average and -34.81% percent below its 100-day simple moving average. However, the stock is currently trading approximately -58.00% below its SMA50 and -44.83% below its SMA200.
Stochastic coefficient K was 26.65% and Stochastic coefficient D was 22.21%, while ATR was 0.3115. Given the Stochastic reading of 28.53% for the 14-day period, the RSI (14) reading has been calculated as 32.85%. As of today, the MACD Oscillator reading stands at 0.0867, while the 14-day reading stands at -0.3490.
Maxim Group upgraded its rating on Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) to a Buy in a note to investors on February 04, 2021. The analysts firm previously had a Hold rating on the stock.Brainstorm Cell Therapeutics Inc. (BCLI) has been rated Buy by analysts. According to 0 brokerage firms, BCLI is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Brainstorm Cell Therapeutics Inc. stock as buy, with 1 recommending it as overweight.
With a median target price of $13.00, the current consensus forecast for the stock is $5.00 – $21.00. Based on these forecasts, analysts predict Brainstorm Cell Therapeutics Inc. (BCLI) will achieve an average price target of $13.00.